Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SHE:301096)
China · Delayed Price · Currency is CNY 50.66
+0.56 (1.12%)
At close: Feb 3, 2026
SHE:301096 Revenue
Hangzhou Bio-Sincerity Pharma-Tech had revenue of 177.53M CNY in the quarter ending September 30, 2025, a decrease of -9.62%. This brings the company's revenue in the last twelve months to 590.33M, down -42.41% year-over-year. In the year 2024, Hangzhou Bio-Sincerity Pharma-Tech had annual revenue of 801.92M, down -21.18%.
Revenue (ttm)
590.33M
Revenue Growth
-42.41%
P/S Ratio
9.20
Revenue / Employee
321.88K
Employees
1,451
Market Cap
5.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 801.92M | -215.52M | -21.18% |
| Dec 31, 2023 | 1.02B | 410.04M | 67.51% |
| Jan 1, 2023 | 607.41M | 233.10M | 62.27% |
| Dec 31, 2021 | 374.31M | 167.06M | 80.61% |
| Dec 31, 2020 | 207.25M | 50.83M | 32.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 53.89B |
| Zhejiang Int'l Group | 33.54B |
| GuangYuYuan Chinese Herbal Medicine | 1.39B |
| Shanghai InnoStar Bio-tech | 829.92M |
| Chongqing Lummy Pharmaceutical | 771.02M |
| Hangzhou Minsheng Healthcare | 744.06M |
| Zhejiang Haisen Pharmaceutical | 510.33M |
| Shandong Keyuan Pharmaceutical | 435.52M |